{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:25:32Z","timestamp":1787235932402,"version":"build-2736575974"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumors. Most patients are diagnosed at advanced or metastatic stages, losing the opportunity for curative surgery. Current systemic treatments for pancreatic cancer remain suboptimal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 68-year-old female presented with upper abdominal pain. Imaging revealed a pancreatic mass, prompting an exploratory laparotomy. Intraoperative frozen section pathology identified metastatic adenocarcinoma nodules near the hepatic artery. The patient was subsequently evaluated and enrolled in a clinical trial. The treatment regimen comprised AG chemotherapy (nab-paclitaxel and gemcitabine) combined with AK112 (a novel bispecific antibody). After 13 administrations of AG chemotherapy and 9 infusions of AK112, imaging evaluation demonstrated partial tumor regression. A multidisciplinary team (MDT) assessment deemed the lesion potentially resec]. The exploratory laparotomy confirmed resectability, and a total pancreatectomy was performed. Postoperative pathology confirmed moderately differentiated pancreatic ductal adenocarcinoma with focal degenerative changes. During postoperative treatment, wound exudate suggestive of intestinal leakage prompted surgical intervention on June 12, 2023. Adjuvant therapy resumed after wound healing but was discontinued in September 2023 due to recurrent incision leakage. Maintenance therapy with tegafur was initiated thereafter. Unfortunately, the patient died of acute myocardial infarction on August 4, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination therapy of AK112 and AG achieved good results in this case, but the broader efficacy of this regimen across the pancreatic cancer population awaits validation through large-scale clinical trials. The ongoing trials are highly anticipated, as successful results could establish AK112 as a novel therapeutic strategy for pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1667445","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:39:58Z","timestamp":1767940798000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["AK112 (PD-1\/VEGF-a bispecific antibody) combined with chemotherapy in locally advanced pancreatic cancer: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Jiuliang","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanguang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuntao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beiyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical beneft with gemcitabine as frst-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.14140568","article-title":"Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection","volume":"274","author":"Pysz","year":"2015","journal-title":"Radiology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds135","article-title":"BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer","volume":"23","author":"Gon\u00e7alves","year":"2012","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.32604\/or.2024.045356","article-title":"Targeting KRAS in pancreatic cancer","volume":"32","author":"Stickler","year":"2024","journal-title":"Oncol Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx343","article-title":"Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study","volume":"28","author":"Schultheis","year":"2017","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/1535-7163.MCT-24-0311","article-title":"Looking beyond checkpoint inhibitor monotherapy: uncovering new frontiers for pancreatic cancer immunotherapy","volume":"24","author":"Giurini","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i35.5094","article-title":"Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancer","volume":"29","author":"Zhou","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102719","article-title":"Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection","volume":"125","author":"Brozos-V\u00e1zquez","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i23.3158","article-title":"Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management","volume":"27","author":"Gupta","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e18266","DOI":"10.1111\/jcmm.18266","article-title":"Combining bulk and scRNA-seq to explore the molecular mechanisms governing the distinct efferocytosis activities of a macrophage subpopulation in PDAC","volume":"28","author":"Zhu","year":"2024","journal-title":"J Cell Mol Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5644\/ama2006-124.479","article-title":"The possible role of immunotherapy in locally advanced pancreatic cancer treatment","volume":"54","author":"Barakat","year":"2025","journal-title":"Acta Med Acad"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000500571","article-title":"A phase 1b\/2 study of the Bruton tyrosine kinase inhibitor ibrutinib and the PD-L1 inhibitor durvalumab in patients with pretreated solid tumors","volume":"97","author":"Hong","year":"2019","journal-title":"Oncology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01321","article-title":"Synergies of antiangiogenic therapy and immune checkpoint blockade in renal cell carcinoma: from theoretical background to clinical reality","volume":"10","author":"Zhou","year":"2020","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e01819","DOI":"10.1002\/advs.202501819","article-title":"Bispecific antibody targeting VEGF\/TGF-\u03b2 Synergizes with local radiotherapy: turning tumors from cold to inflamed and amplifying abscopal effects","volume":"12","author":"Lyu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0244","article-title":"Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma","volume":"3","author":"Liu","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox208","article-title":"Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143","volume":"20","author":"Omuro","year":"2018","journal-title":"Neuro Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-019-1329-2","article-title":"The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications","volume":"37","author":"Tamura","year":"2019","journal-title":"Med Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1667445\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:39:58Z","timestamp":1767940798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1667445\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":28,"alternative-id":["10.3389\/fonc.2025.1667445"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1667445","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"1667445"}}